Cara Therapeutics Inc (CARA)

4.77 -0.11 (-2.25%) USD  |  NASDAQ  |  Jan 08, 13:02
More

Cara Therapeutics SG&A Expense (Quarterly): 6.402M for Sept. 30, 2024

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for CARA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense Definition

View SG&A Expense Definition
Start Trial

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
NeuroMetrix Inc 1.754M
Johnson & Johnson 5.278B
Sarepta Therapeutics Inc 128.20M
Corvus Pharmaceuticals Inc 2.033M
NovaBay Pharmaceuticals Inc 2.65M